# Cellectar Biosciences (CLRB) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/CLRB
## Company Profile
- Ticker: CLRB
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 2.6 USD
- Market cap: 21897564.880000003 USD
- Last updated: 2026-08-12
## Business Overview
### Phospholipid Drug Conjugate Platform
Cellectar Biosciences develops cancer therapies using its Phospholipid Drug Conjugate platform, which is designed to deliver radioisotopes selectively to malignant cells while limiting off-target exposure.
### Iopofosine I 131
Iopofosine I 131 is the company’s lead radioconjugate and has produced clinical evidence in relapsed or refractory Waldenström macroglobulinemia. It has also been studied in multiple myeloma and central nervous system lymphoma.
### CLR 125 Solid-Tumor Program
CLR 125 carries the Auger-emitting isotope iodine-125 and is being evaluated initially in triple-negative breast cancer, with potential application in lung and colorectal cancers.
### Regulatory Strategy
Cellectar plans a confirmatory study of iopofosine in Waldenström macroglobulinemia to support a potential FDA filing under the Accelerated Approval pathway.
## Why The Stock Is Moving

The latest monitored company update is “Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Initiation of enrollment in the confirmatory Phase 3 iopofosine I 131 study in Waldenström macroglobulinemia.
- NDA submission for iopofosine I 131 under the accelerated-approval pathway in mid-2027.

## Drug Assets

- iopofosine I 131

## Recent News
- 2026-08-13 11:15 EST — [Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-reports-second-quarter-2026-financial-results-and-provides-0e994c01) — Source: Cellectar Biosciences
- 2026-07-30 12:05 EST — [Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-to-report-second-quarter-financial-results-and-host-a-conf-1d91f28e) — Source: Cellectar Biosciences
- 2026-07-15 11:30 EST — [Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-announces-publication-of-phase-1-study-of-iopofosine-i-131-1d5d4326) — Source: Cellectar Biosciences
- 2026-06-01 12:05 EST — [Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-to-highlight-compelling-new-efficacy-data-from-phase-2b-clover-wam-study-of-iopofosine-i-131-in-r-r-waldenstroem-macroglobulinemia-at-the-american-society-of-clinical-oncology-annual-meeting) — Source: Cellectar Biosciences
- 2026-05-14 11:15 EST — [Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-reports-first-quarter-2026-financial-results-and-provides-corporate-updates) — Source: Cellectar Biosciences